{"id":"oxycodone-hcl-controlled-release-tablets","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"20-30","effect":"Drowsiness"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Pruritus"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone is a semi-synthetic opioid agonist that acts primarily on mu (μ) opioid receptors in the brain and spinal cord. The controlled-release formulation provides sustained drug delivery over an extended period, allowing for less frequent dosing compared to immediate-release formulations. This mechanism produces analgesia, sedation, and other opioid effects through modulation of pain perception and emotional response to pain.","oneSentence":"Oxycodone HCl binds to opioid receptors in the central nervous system to block pain signal transmission and provide analgesia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:16.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain requiring continuous opioid therapy"},{"name":"Postoperative pain management"}]},"trialDetails":[{"nctId":"NCT07348627","phase":"PHASE3","title":"Opioid-Sparing Joint Replacement","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-02","conditions":"Pain Management, Opioid Consumption","enrollment":120},{"nctId":"NCT04044820","phase":"NA","title":"Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-03-04","conditions":"Opioid Use","enrollment":292},{"nctId":"NCT06434233","phase":"PHASE4","title":"Opioid Use After Laparoscopic Salpingectomy","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-25","conditions":"Opioid Use, Post-operative Pain, Sterility, Female","enrollment":120},{"nctId":"NCT05842044","phase":"PHASE2","title":"NSAID Use After Robotic Partial Nephrectomy","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-09-15","conditions":"Kidney Cancer, Renal Cancer, Renal Neoplasm","enrollment":110},{"nctId":"NCT07001709","phase":"PHASE4","title":"Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)","status":"RECRUITING","sponsor":"Deventer Ziekenhuis","startDate":"2024-04-12","conditions":"Prostate Cancer, Pain Cancer","enrollment":29},{"nctId":"NCT05070338","phase":"NA","title":"Postoperative Nudges to Reduce Opioid Prescribing","status":"COMPLETED","sponsor":"RAND","startDate":"2021-10-19","conditions":"Opioid Prescribing","enrollment":640},{"nctId":"NCT03987022","phase":"PHASE4","title":"ICE-T Pain Regimen for Total Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2019-08-01","conditions":"Opioid Substitution Treatment","enrollment":66},{"nctId":"NCT05567354","phase":"PHASE1","title":"A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2022-06-10","conditions":"Recreational Drug Use","enrollment":27},{"nctId":"NCT05571345","phase":"PHASE1","title":"A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2022-10-05","conditions":"Recreational Drug Use","enrollment":32},{"nctId":"NCT06561035","phase":"PHASE3","title":"ACL-R Opioid Sparing Study","status":"ENROLLING_BY_INVITATION","sponsor":"Campbell Clinic","startDate":"2024-09-01","conditions":"Anterior Cruciate Ligament Injuries","enrollment":56},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT04710277","phase":"NA","title":"Novel Multimodal Pain Control Protocol for Minimally Invasive Gynecologic Surgery","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2021-04-19","conditions":"Postoperative Pain, Narcotic Use, Cryotherapy Effect","enrollment":54},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT04246554","phase":"PHASE3","title":"Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2019-05-21","conditions":"ACL Injury, Postoperative Pain","enrollment":49},{"nctId":"NCT03586934","phase":"PHASE3","title":"Multimodal Analgesia in Shoulder Arthroplasty","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2018-06-01","conditions":"Shoulder Pain, Opioid Use","enrollment":""},{"nctId":"NCT03845881","phase":"EARLY_PHASE1","title":"Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-04-10","conditions":"Total Knee Arthroplasty","enrollment":45},{"nctId":"NCT04448457","phase":"NA","title":"Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Tivoli","startDate":"2017-09-01","conditions":"Postoperative Pain","enrollment":72},{"nctId":"NCT04132011","phase":"PHASE4","title":"Dosing Intervals of Opioid Medication for Chronic Pain","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT01192295","phase":"PHASE3","title":"Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2010-11","conditions":"Pain","enrollment":155},{"nctId":"NCT03319277","phase":"NA","title":"A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2017-10-13","conditions":"Postoperative Pain, Opioid Use","enrollment":118},{"nctId":"NCT03478423","phase":"NA","title":"Opioid Analgesics for Acute Fracture Pain in Adults Discharged From the ED","status":"TERMINATED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2018-02-05","conditions":"Acute Pain","enrollment":5},{"nctId":"NCT04003350","phase":"NA","title":"The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","startDate":"2017-12-21","conditions":"Osteo Arthritis Knee","enrollment":216},{"nctId":"NCT03168425","phase":"NA","title":"Opioid Prescribing After Cesarean Delivery","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-06-14","conditions":"Surgery, Opioid Use","enrollment":190},{"nctId":"NCT03765346","phase":"PHASE1","title":"A Comparison of How Likely it is That Different Tablets of Oxycodone Will be Broken up and Snorted by Adults Who Sometimes Take Drugs for Pleasure","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2018-07-24","conditions":"Substance Abuse","enrollment":123},{"nctId":"NCT00743587","phase":"PHASE1","title":"A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Osteoarthritis Thumbs","enrollment":36},{"nctId":"NCT00513656","phase":"PHASE2","title":"A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2007-09","conditions":"Cancer, Pain, Constipation","enrollment":230},{"nctId":"NCT01197261","phase":"PHASE2","title":"OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-09","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Pain","enrollment":120},{"nctId":"NCT01971632","phase":"PHASE3","title":"A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2005-01","conditions":"Subjects With Moderate to Severe, Chronic Nonmalignant Pain","enrollment":463},{"nctId":"NCT01112644","phase":"PHASE3","title":"Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-04","conditions":"Moderate to Severe Idiopathic RLS With Daytime Symptoms","enrollment":205},{"nctId":"NCT01677065","phase":"","title":"A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT03475862","phase":"PHASE1","title":"Nasal Human Abuse Potential of PTI-821","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2017-05-15","conditions":"Opioid Abuse Nondependent","enrollment":38},{"nctId":"NCT02716857","phase":"PHASE3","title":"Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Egalet Ltd","startDate":"2016-03","conditions":"Moderate-to-severe Chronic Low Back Pain","enrollment":549},{"nctId":"NCT03045484","phase":"NA","title":"Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-05","conditions":"Nasopharyngeal Carcinoma","enrollment":70},{"nctId":"NCT00679614","phase":"PHASE3","title":"Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Hip Arthroplasty, Knee Arthroplasty, Spinal Anesthesia","enrollment":45},{"nctId":"NCT01775189","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT00853892","phase":"PHASE1","title":"Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2005-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT00853268","phase":"PHASE1","title":"Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2005-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT01986283","phase":"PHASE1","title":"Abuse Potential Study of PF-00345439","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-11","conditions":"Opioid Users","enrollment":67},{"nctId":"NCT01358526","phase":"PHASE3","title":"Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-05","conditions":"Low Back Pain","enrollment":1095},{"nctId":"NCT01014559","phase":"PHASE3","title":"Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","status":"TERMINATED","sponsor":"Mundipharma SAS","startDate":"2010-02","conditions":"Constipation, Pain","enrollment":225},{"nctId":"NCT01369615","phase":"PHASE3","title":"Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-10","conditions":"Pain","enrollment":23},{"nctId":"NCT01427283","phase":"PHASE3","title":"A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":450},{"nctId":"NCT01427270","phase":"PHASE3","title":"Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":455},{"nctId":"NCT00361504","phase":"PHASE3","title":"A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain","enrollment":1123},{"nctId":"NCT01439100","phase":"PHASE3","title":"A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-10","conditions":"Parkinson's Disease With Severe Pain","enrollment":172},{"nctId":"NCT00805142","phase":"PHASE2","title":"Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-11","conditions":"Pain, Cancer","enrollment":78},{"nctId":"NCT01160614","phase":"PHASE1","title":"Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2010-07","conditions":"Opioid Analgesia","enrollment":30},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98},{"nctId":"NCT00463047","phase":"PHASE3","title":"Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain","status":"COMPLETED","sponsor":"Cephalon","startDate":"2007-07","conditions":"Chronic Pain","enrollment":323},{"nctId":"NCT00813488","phase":"PHASE3","title":"Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Cephalon","startDate":"2008-12","conditions":"Chronic Pain","enrollment":213},{"nctId":"NCT00784277","phase":"PHASE3","title":"A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-10","conditions":"Joint Diseases, Arthritis, Osteoarthritis","enrollment":597},{"nctId":"NCT00745069","phase":"PHASE2","title":"Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-07","conditions":"Osteoarthitis, Chronic Pain, Knee Pain","enrollment":670},{"nctId":"NCT01344720","phase":"PHASE4","title":"Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain","status":"UNKNOWN","sponsor":"Azienda Sanitaria Locale 4, Teramo","startDate":"2011-05","conditions":"Low Back Pain","enrollment":250},{"nctId":"NCT01127906","phase":"PHASE1","title":"Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-06","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OxyContin"],"phase":"phase_3","status":"active","brandName":"Oxycodone HCl controlled-release tablets","genericName":"Oxycodone HCl controlled-release tablets","companyName":"Purdue Pharma LP","companyId":"purdue-pharma-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone HCl binds to opioid receptors in the central nervous system to block pain signal transmission and provide analgesia. Used for Moderate to severe chronic pain requiring continuous opioid therapy, Postoperative pain management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}